Clinical Trial

Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

Study acronym: HFrecEF
Recruiting
View on ClinicalTrials.gov →
Summary
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-05.
Status change: Not Yet Recruiting → Recruiting 2026-03-23
Trial Details
NCT Number NCT06724653
Lead Sponsor Chungnam National University Hospital
Conditions Heart Failure, Ejection Fraction, Recovery of Function
Enrollment 150 participants
Start Date 2025-03-06
Primary Completion 2025-05-26 (estimated)
Study Completion 2027-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-27